{
    "xml": "<topic id=\"PHP80936\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/engerix-b\" basename=\"engerix-b\" title=\"Engerix B\">\n<title>Engerix B<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP81428\" outputclass=\"indicationsAndDose\" rev=\"1.55\" parent=\"/clinical-medicinal-product-information/engerix-b\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>10&#8239;micrograms for 1 dose, then 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates, infants and young children; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;15 years</p>\n<p>10&#8239;micrograms for 1 dose, then 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>20&#8239;micrograms for 1 dose, then 20&#8239;micrograms after 1&#8239;month for 1 dose, followed by 20&#8239;micrograms after 5&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;micrograms for 1 dose, then 20&#8239;micrograms after 1&#8239;month for 1 dose, followed by 20&#8239;micrograms after 5&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection (accelerated schedule)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;15 years</p>\n<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>20&#8239;micrograms every 1&#8239;month for 3 months, followed by 20&#8239;micrograms after 9&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;micrograms every 1&#8239;month for 3 months, followed by 20&#8239;micrograms after 9&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection (accelerated schedule in exceptional cases, e.g. for travellers departing within 1 month)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;micrograms for 1 dose, then 20&#8239;micrograms after 7&#8239;days for 1 dose, followed by 20&#8239;micrograms after 14&#8239;days for 1 dose, followed by 20&#8239;micrograms after 11&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection, alternative schedule</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 11&#8211;15 years</p>\n<p>20&#8239;micrograms for 1 dose, followed by 20&#8239;micrograms after 6&#8239;months, this schedule is not suitable if high risk of infection between doses or if compliance with second dose uncertain, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection (for neonates born to hepatitis B surface antigen-positive mother)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>10&#8239;micrograms once a month for 3 months, first dose to be given at birth with hepatitis B immunoglobulin injection (separate site), followed by 10&#8239;micrograms after 10&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>10&#8239;micrograms every 1&#8239;month for 2 months, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;15 years</p>\n<p>10&#8239;micrograms every 1&#8239;month for 2 months, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>40&#8239;micrograms every 1&#8239;month for 3 months, followed by 40&#8239;micrograms after 4&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>40&#8239;micrograms every 1&#8239;month for 3 months, followed by 40&#8239;micrograms after 4&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients (accelerated schedule))</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup neonate\">\n<p>Neonate</p>\n<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 10&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;15 years</p>\n<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 10&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP80936",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/engerix-b",
    "basename": "engerix-b",
    "title": "Engerix B",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection",
                        "html": "Immunisation against hepatitis B infection"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "10 micrograms for 1 dose, then 10 micrograms after 1 month for 1 dose, followed by 10 micrograms after 5 months for 1 dose, anterolateral thigh is preferred site in neonates, infants and young children; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.",
                        "html": "<p>10&#8239;micrograms for 1 dose, then 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates, infants and young children; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>"
                    }
                ],
                "child": [
                    {
                        "textContent": "10 micrograms for 1 dose, then 10 micrograms after 1 month for 1 dose, followed by 10 micrograms after 5 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms for 1 dose, then 10&#8239;micrograms after 1&#8239;month for 1 dose, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "1 month&#8211;15 years"
                    },
                    {
                        "textContent": "20 micrograms for 1 dose, then 20 micrograms after 1 month for 1 dose, followed by 20 micrograms after 5 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>20&#8239;micrograms for 1 dose, then 20&#8239;micrograms after 1&#8239;month for 1 dose, followed by 20&#8239;micrograms after 5&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "20 micrograms for 1 dose, then 20 micrograms after 1 month for 1 dose, followed by 20 micrograms after 5 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>20&#8239;micrograms for 1 dose, then 20&#8239;micrograms after 1&#8239;month for 1 dose, followed by 20&#8239;micrograms after 5&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection (accelerated schedule)",
                        "html": "Immunisation against hepatitis B infection (accelerated schedule)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "10 micrograms every 1 month for 3 months, followed by 10 micrograms after 9 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>"
                    }
                ],
                "child": [
                    {
                        "textContent": "10 micrograms every 1 month for 3 months, followed by 10 micrograms after 9 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 9&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "1 month&#8211;15 years"
                    },
                    {
                        "textContent": "20 micrograms every 1 month for 3 months, followed by 20 micrograms after 9 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>20&#8239;micrograms every 1&#8239;month for 3 months, followed by 20&#8239;micrograms after 9&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "20 micrograms every 1 month for 3 months, followed by 20 micrograms after 9 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>20&#8239;micrograms every 1&#8239;month for 3 months, followed by 20&#8239;micrograms after 9&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection (accelerated schedule in exceptional cases, e.g. for travellers departing within 1 month)",
                        "html": "Immunisation against hepatitis B infection (accelerated schedule in exceptional cases, e.g. for travellers departing within 1 month)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "20 micrograms for 1 dose, then 20 micrograms after 7 days for 1 dose, followed by 20 micrograms after 14 days for 1 dose, followed by 20 micrograms after 11 months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>20&#8239;micrograms for 1 dose, then 20&#8239;micrograms after 7&#8239;days for 1 dose, followed by 20&#8239;micrograms after 14&#8239;days for 1 dose, followed by 20&#8239;micrograms after 11&#8239;months for 1 dose, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection, alternative schedule",
                        "html": "Immunisation against hepatitis B infection, alternative schedule"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "20 micrograms for 1 dose, followed by 20 micrograms after 6 months, this schedule is not suitable if high risk of infection between doses or if compliance with second dose uncertain, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>20&#8239;micrograms for 1 dose, followed by 20&#8239;micrograms after 6&#8239;months, this schedule is not suitable if high risk of infection between doses or if compliance with second dose uncertain, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "11&#8211;15 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection (for neonates born to hepatitis B surface antigen-positive mother)",
                        "html": "Immunisation against hepatitis B infection (for neonates born to hepatitis B surface antigen-positive mother)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "10 micrograms once a month for 3 months, first dose to be given at birth with hepatitis B immunoglobulin injection (separate site), followed by 10 micrograms after 10 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms once a month for 3 months, first dose to be given at birth with hepatitis B immunoglobulin injection (separate site), followed by 10&#8239;micrograms after 10&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients)",
                        "html": "Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "10 micrograms every 1 month for 2 months, followed by 10 micrograms after 5 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 2 months, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>"
                    }
                ],
                "child": [
                    {
                        "textContent": "10 micrograms every 1 month for 2 months, followed by 10 micrograms after 5 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 2 months, followed by 10&#8239;micrograms after 5&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "1 month&#8211;15 years"
                    },
                    {
                        "textContent": "40 micrograms every 1 month for 3 months, followed by 40 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>40&#8239;micrograms every 1&#8239;month for 3 months, followed by 40&#8239;micrograms after 4&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "40 micrograms every 1 month for 3 months, followed by 40 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>40&#8239;micrograms every 1&#8239;month for 3 months, followed by 40&#8239;micrograms after 4&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; not to be injected into the buttock (vaccine efficacy reduced).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients (accelerated schedule))",
                        "html": "Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients (accelerated schedule))"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "neonate": [
                    {
                        "textContent": "10 micrograms every 1 month for 3 months, followed by 10 micrograms after 10 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 10&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.</p>"
                    }
                ],
                "child": [
                    {
                        "textContent": "10 micrograms every 1 month for 3 months, followed by 10 micrograms after 10 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).",
                        "html": "<p>10&#8239;micrograms every 1&#8239;month for 3 months, followed by 10&#8239;micrograms after 10&#8239;months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in adults and older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttock (vaccine efficacy reduced).</p>",
                        "ageGroup": "1 month&#8211;15 years"
                    }
                ]
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}